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Background: Peripheral arterial disease (PAD) is a progressive vascular disease associated with a high risk of car-
diovascular morbidity and death. Antithrombotic prevention is usually applied by prescribing the antiplatelet
agent aspirin. However, in patients with PAD aspirin fails to provide protection against myocardial infarction
and death, only reducing the risk of ischemic stroke. Platelets may play a role in disease development, but this
has not been tested by proper mechanistic studies. In the present study, we performed a systematic evaluation
of platelet reactivity in whole blood from patients with PAD using two high-throughput assays, i.e. multi-
agonist testing of platelet activation by flow cytometry and multi-parameter testing of thrombus formation on
spotted microarrays.
Methods: Bloodwas obtained from 40 patients (38 on aspirin) with PAD inmajority class IIa/IIb and from 40 age-
matched control subjects. Whole-blood flow cytometry and multiparameter thrombus formation under high-
shear flow conditions were determined using recently developed and validated assays.
Results: Flow cytometry of whole blood samples from aspirin-treated patients demonstrated unchanged high
platelet responsiveness towards ADP, slightly elevated responsiveness after glycoprotein VI stimulation, and de-
creased responsiveness after PAR1 thrombin receptor stimulation, compared to the control subjects. Most pa-
rameters of thrombus formation under flow were similarly high for the patient and control groups. However,
in vitro aspirin treatment caused a marked reduction in thrombus formation, especially on collagen surfaces.
When compared per subject, markers of ADP- and collagen-induced integrin activation (flow cytometry) strong-
ly correlated with parameters of collagen-dependent thrombus formation under flow, indicative of a common,
subject-dependent regulation of both processes.
Conclusion: Despite of the use of aspirin, most platelet activation properties were in the normal range in whole-
blood from class II PAD patients. These data underline the need for more effective antithrombotic
pharmacoprotection in PAD.© 2015 Elsevier Ltd. All rights reserved.Introduction
Peripheral arterial disease (PAD) is a systemic vascular disorderwith
manifestations of atherosclerosis in particular in the lower extremities,
resulting in obstruction of the arterial blood flow, and strongly associat-
ed with cardiovascular events [1–3]. In the Western world, aalMolecularMedicine (CTMM),
ular Centre (HVC), Maastricht
ers had no role in study design,
ation of the manuscript.
IM, Maastricht University, P.O.
43 3881671.
.nl (J.W.M. Heemskerk).considerable part of the elderly population appears to have characteris-
tics of PAD, albeit the affected subjects often remain asymptomatic [4,5].
Symptomatic patients, already at an early stage (Fontaine class IIa/IIb),
suffer from intermittent claudication and cannot walk a long distance
without feeling pain [2]. At later stages (Fontaine classes III/IV), PAD pa-
tients progressively suffer from chronic and critical leg ischemia [2].
While it is recognized that systemic atherosclerosis is one of the un-
derlying diseases of PAD, the pathophysiology of this disease is still not
well understood. One of the early concepts was that aberrant coagula-
tion, inflammation and platelet activity in these patients lead to ongoing
thrombogenesis in the lower extremities [6]. In agreement with this,
markers of systemic coagulation such as levels of D-dimer are increased
in patients with PAD, but it is unclear whether this also reflects causality
Table 1
Baseline characteristics of control subjects and PAD patients. Data are represented as me-
dians (ranges).
Subject characteristics Controls Patients P
General
Age, years 67 (60 - 71) 67 (65 - 72)
Male gender, n 22/40 24/40
Body mass index, kg/m2 26 (23.4 - 27.8) 26.1 (23.7 - 29.3)
Diagnosis PAD (Fontaine), n
I, IIa/IIb, III 0, 0, 0 1, 37, 2
Medical history, n
Diabetes mellitus 1 5
Hypertension 13 29
Aspirin intake 0 38
Anticoagulant intake 0 0
Hemostatic variables
Platelet count, x109/L 255 (205 - 291) 249 (213 - 284) n.s.
Mean platelet volume, fL 10.8 (10.2 - 11.4) 11.1 (10.4 - 11.9) n.s.
Hematocrit, L/L 0.44 (0.42 - 0.47) 0.43 (0.39 - 0.45) n.s.
Leukocyte count, x109/L 6.15 (5.60 - 7.45) 7.50 (6.03 - 9.13) 0.003
D-dimers, ng/mL 366 (259 - 520) 528 (363 - 835) 0.005
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reactive protein are elevated [10,11]. There is also ample evidence in
the literature for increased platelet activation and aggregation in PAD
[12–15], although this is not an undisputed finding [8,16,17]. The role
of platelets in PADmay indeed be complex. On the one hand, antiplate-
let treatment with aspirin, inhibiting thromboxane formation, is a stan-
dard therapy for PAD patients, with inhibitors of the platelet P2Y12
receptors (clopidogrel, prasugrel) as effective alternatives [18]. On the
other hand, there is evidence that in these patients, even after aspirin
treatment, platelet functions remain high [19], platelet-monocyte ag-
gregates are still formed [20], and platelet cleavage products such as sol-
uble CD40L accumulate in the plasma [21]. Since PAD in many patients
is a progressive disease with high cardiovascular risk, the question is
whether residual high on-treatment platelet activity may contribute
to the disease progression.
In recent years, a number of whole-blood based tests for detailed
and overall platelet phenotyping in bleeding and thrombosis have
been developed and validated. Plate-wells based flow cytometric tests
allow simultaneous determination of key platelet responses, i.e. fibrino-
gen binding (integrin αIIbβ3 activation) and secretion (P-selectin expo-
sure) in response to a panel of receptor agonists [22,23]. Such flow
cytometric tests are advantageous in detecting changed platelet activa-
tion in thrombotic patients [24]. Furthermore, flow chamber devices for
whole-blood perfusion over a thrombogenic surface like collagen have
appeared to be highly valuable in detecting a loss or gain of platelet
function, supporting their use as ex vivo assays reflecting arterial throm-
bus formation [25–27]. Recently, we have extended this method into a
multi-parameter platelet function test to assess thrombus formation
on arrays of microspotted platelet-adhesive surfaces [28].
In the present paper, we used both high-throughput whole-blood
assays, i.e.multi-agonist testing of platelet activation by flow cytometry
and multi-parameter testing of thrombus formation on microarray
spots, for detailed evaluation of the platelets in patients with PAD re-
ceiving aspirin. The data show that platelet function in these patients




Included were 40 patients with established PAD. Patients were se-
lected based on a decrease in the ankle brachial index b0.9 [29,30]
and most of them suffered from a stage IIa/IIb disorder according to
the Fontaine classification [2]. As a control group, 40 healthy control
subjects were included with similar age and gender. Fitness (i.e., non-
disease state) of the control subjects was assessed with the Edinburgh
claudication questionnaire [31]. Medication use was checked in all pa-
tient and control subjects by personal interview. Exclusion criteria for
patients and controls were: proved coagulation or chronic inflammato-
ry disorders, active infection, malignancy, anti-phospholipid syndrome,
pregnancy and/or prescribed antiplatelet or anticoagulant medicines
other than aspirin. The study was approved by the Medical Ethics Com-
mittee of the Maastricht University Medical Center. All patients and
healthy subjects gave written informed consent for participation ac-
cording to the declaration of Helsinki.
Blood Collection
Blood was drawn from subjects in resting condition, and collected
into 10 mL tubes containing 3.2% trisodium citrate. Portions of the
whole-blood were directly used for flow cytometric and flow chamber
assays. Separate blood samples were collected into 4 mL EDTA tubes
(BD Vacutainer, Breda, the Netherlands) for determination of
haemoglobin and blood cell counts with a Sysmex XN-9000 analyzer
(Kobe, Japan).Whole-Blood Flow Cytometry
Agonist-induced platelet activation was assessed by an optimized
and validated test using diluted whole-blood samples without centrifu-
gation steps [22]. In brief, a 96-well plate was thawed, containing phy-
coerythrin (PE)-conjugated anti-P-selectin mAb (BD 555524,
Pharmingen, Franklin Laker, NJ) and FITC-conjugated anti-fibrinogen
Ab (F011102, Dako, Denmark) together with varying concentrations
of ADP (01897-1G, Sigma-Aldrich, Zwijndrecht, the Netherlands), colla-
gen peptide (CRP-xl, Cambridge University, UK, a generous gift) [22] or
TRAP-6 (H2936.0025, Bachem, Weil am Rein, Germany); volume was
50 μL in buffer A (10 mM Hepes, 150 mM NaCl, 5 mM KCl, 1 mM
MgCl2). Activations were started by adding to each well 5 μL of blood,
while mixing. Final agonist concentrations were: 0.1-2.7 μM ADP, 5-
135 ng/mL collagen peptide or 0.4-3.2 μM TRAP-6. A separate row did
not contain platelet agonists and served as vehicle. After 20 minutes of
activation, 500 μL fixation solution (0.9% NaCl, 0.2% formaldehyde)
was added to each well. Integrin activation and P-selectin expression
in platelets were analyzed on an Accuri C6 flow cytometer (Becton
and Dickinson, CA; 10,000 events), as described [24]. Data are repre-
sented as mean fluorescence intensities.
Whole-Blood Thrombus Formation on Microspots
Whole-blood thrombus formation under flow was investigated with
the Maastricht flow chamber (depth 50 μm, width 3 mm, length
30 mm), employing a newly developed and validated multi-parameter
assay in combinationwith threemicrospots [28].Where indicated, control
blood samples were pre-incubated with lysine acetylsalicylate for 10
minutes at 37 °C (100 μM, Aspegic, Sanofi, Gouda, the Netherlands).
Microspots on glass coverslips were prepared by applying 0.5 μL collagen
type I Horm (100 μg/mL), von Willebrand factor (vWF, 50 μg/mL) com-
bined with CLEC-2 agonist rhodocytin (250 μg/mL), and vWF plus fibrino-
gen (250 μg/mL). Sources of microspots were as described before [32].
Citrate whole-blood perfusion was at arterial wall-shear rate of 1600 s–1
for 3.5 minutes. Brightfield images were taken from all three microspots,
while chambers were stained with Alexa Fluor (AF) 647-labeled annexin
A5 (1:200, A23204, Life Technology, Eugene, OR) and FITC-labelled anti-
P-selectin mAb (1:40, A07790, Beckman Coulter, Woerden, the
Netherlands) in buffer B (10 mM Hepes, 136 mM NaCl, 2.7 mM KCl,
2 mMMgCl2, 2 mM CaCl2, 0.1% glucose, 0.1% bovine serum albumin, 5 U/
mL fragmin (low-molecular weight heparin) (RVG20607, Pfizer, Capelle
a/d IJssel) and 1 U/mL unfractionated heparin (1760 U/mL, 125 K1336,
Sigma), pH 7.45). The anticoagulants were added to all Ca2+-containing
perfusion buffers to prevent thrombin and fibrin generation. Images of
FITC and AF647 fluorescence were captured after a short rinse with buffer
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(Life Technology) was used, basically as described elsewhere [28].
Whole-blood thrombus formation under flow was also assayed in
real-time using a microfluidics polydimethyl siloxane (PDMS) flow
chamber with a straight 1mmwide x 50 μmheight channel, principally
as described [33], but without stenosis. The disposable chamber was
prepared with a Sylgard 184 kit, by mixing 43 g of silicone elastomer
with 7 g curing agent (Dow Corning, Wiesbaden, Germany). The
degased mixture was poured into a round mold containing water to
harden at room temperature. The flow channel inlet and outlet were
made using a 3 mm biopsy punch and a blunt syringe needle, respec-
tively. The flow chip was mounted onto a glass coverslip, coated with
collagen type I Horm (100 μg/mL) [34], fixed with a pressure plate,
and pre-rinsed. Whole-blood perfusion, using a pulse-free syringe
pump (pull mode), was performed as described [35]. Blood samplesFig. 1. Activation tendency of platelets from PAD patients and control subjects. Diluted who
indicated doses of 0.1-2.7 μM ADP (A, B), 5-135 ng/mL CRP-xl (C, D) or 0.4-3.2 μM TRAP-6 (E, F
(right panels) were determined by flow cytometry, using a FITC-anti fibrinogen and a PE-anti-P
platelets. Patients using aspirin are represented by open squares. Bars indicate mean and S.D. v(300 μL) were pre-labeled with 0.5 μg/mL DiOC6 (6975, AnaSpec,
San Jose, CA), and flowed at a wall-shear rate of 1600 s–1 for 4 minutes.
Microscopic images of deposition of fluorescently labeled platelets were
taken as previously described [28], and analyzed for increases in
fluorescence.Microscopic Imaging and Analysis
Phase-contrast images were analyzed for surface-area-coverage and
integrated feature size, using a standardized journal inMetamorph soft-
ware [36]. Images were also assessed for morphological score from 0
(no platelet adhesion) to 5 (large platelet thrombi) [28]. Fluorescence
images of antibody staining were analyzed for surface-area-coverage
above background with the program Image J (open access).le-blood from control subjects (c) or PAD patients (p) was stimulated in plate- wells with
). Binding of fibrinogen to the platelets (left panels) and P-selectin expression of platelets
-selectinmAb, respectively. Indicated are per subject the percentages of positively stained
alues (n = 40), *P b 0.05.
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Group comparisons were performed using the Mann-Whitney U-
test for continuous variables. Assay parameters were compared using
the Spearman correlation test. The statistical package for the Social Sci-
ences version 22was used (SPSS, Chicago, IL). P -values b0.05were con-
sidered to be significant.Fig. 2. Thrombus formationwith blood frompatients and controls atmicrospot surfaces.W
of 1600 s-1 over microspots containing collagen type I (A), vWF/rhodocytin (B), and vWF/fibrin
expression (middle) or phosphatidylserine exposure (right) from a representative control subResults
Undiminished Platelet Activation in Whole-Blood from PAD Patients on
Aspirin
Baseline characteristics of the 40 control subjects and 40 PAD patients
were comparable for age, gender and body mass index (Table 1). Withhole blood from control subjects or patients was perfused for 3.5minutes atwall shear rate
ogen (C). Shown are typical brightfield images (left) and fluorescence images of P-selectin
ject and patient. Bars = 20 μm.
517J.P. van Geffen et al. / Thrombosis Research 135 (2015) 513–520respect to themedical history, the patients (vs. controls) more frequently
suffered fromdiabetesmellitus (5 vs. 1) and hypertension (29 vs. 13), and
in vast majority used prescribed aspirin (38 vs. 0). All patients, and none
of the control subjects, were diagnosed as PAD with confirmed Fontaine
classification IIa/IIb (37 out of 40). Most hemostatic variables of the PAD
patientswere in thenormal range, but leukocyte counts andplasma levels
of the coagulation product, D-dimers, were significantly increased in the
patient group (Table 1).
Platelet activation tendency was measured in diluted whole blood
samples, using a validated, 96-plate-well-based flow cytometric test,Fig. 3. Parameters of thrombus formationwith blood from patients and controls.Whole blo
described for Fig. 2. Shown are analyzed data per subject of brightfield images of morpholog
phosphatidylserine (D). Patients using aspirin are represented by open squares. Bars indicate min which both integrinαIIbβ3 activation and P-selectin exposure are de-
termined in response to dose ranges of the key agonists, ADP (stimulat-
ing P2Y12/P2Y1 receptors), CRP-xl (stimulating the collagen receptor
glycoprotein VI) and TRAP-6 (stimulating the thrombin receptor
PAR1) [22]. For various agonists, intra- and inter-individual variation
coefficients of the test were b10% and b15%, respectively, for the area
under the curve [37].
In response to the weak agonist ADP, platelets from patients and
control subjects showed a dose-dependent increase in integrin activa-
tion (fibrinogen binding) and limited P-selectin expression (Fig. 1A,od from control subjects (c) and PAD patients (p) was perfused over coatedmicrospots, as
ical score (A) and platelet deposition (B); and of staining for P-selectin (C) and exposed
ean and S.D. values (n = 40), *P b 0.05.
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edly differ between the patient and control groups. Platelet stimulation
with CRP-xl (Fig. 1C,D) or TRAP-6 (Fig. 1E,F) resulted in dose-dependent
increases in integrin activation and P-selectin expression that, with
these stronger agonists, reached maximal levels at high doses. At
lower CRP-xl concentrations, both integrin activation and P-selectin ex-
pression were significantly higher in the patient group than in the con-
trol group (P ≤ 0.037), but ranges were overlapping. In contrast, in
response to higher doses of TRAP-6, integrin activation (P = 0.021)
and P-selectin expression (P≤ 0.015)were significantly lower in the pa-
tient group compared to the controls. Two of the patients did not use as-
pirin. In blood samples from these patients, agonist-induced integrin
activation and P-selectin expression were mostly but not always in
the higher ranges (see Fig. 1). Upon stimulationwith ADP, no significant
effect of aspirin treatments was observed (not shown). This is in agree-
ment with the known sensitivity for aspirin of glycoprotein VI-induced
platelet responses [38]. Taken together, these data indicate that, in spite
of the use of aspirin, the platelets from PAD patients were in general
similarly high in response as the platelets from control subjects, with
only reduced activity at high TRAP-6 doses.Essentially Unchanged Thrombus Formation in Patient Whole Blood
Whole-blood thrombus formation was tested on three microspots,
representing adhesive ligands for major platelet receptors, i.e. collagen
type I (activating via glycoprotein VI and integrin α2β1), vWF/
rhodocytin (acting via GPIb and CLEC-2 receptors), and vWF/fibrinogen
(acting via GPIb and integrin αIIbβ3). The presence of vWF (also binding
to collagen) allowed thrombus formation to be assessed at high, arterial
shear rates [28]. On collagen, large platelet aggregates were formed,
staining positively for P-selectin, and individual platelets in the throm-
bus were present, staining positively with annexin A5 for
phosphatidylserine exposure (Fig. 2A), as established before [39]. On
vWF/rhodocytin smaller aggregates formed, while staining for P-
selectin and phosphatidylserine exposure was still high (Fig. 2B). On
vWF/fibrinogen mostly single platelets adhered with P-selectin but no
phosphatidylserine exposure (Fig. 2C). Principal assay parameters per
surface were obtained following quantitative analysis of the recorded
images, according to standard protocols [36]. Thesewere:morphological
score, platelet deposition (surface-area-coverage of brightfield images),
integrated feature size (weighted cumulative size of platelet aggregates),
and extent of P-selectin and phosphatidylserine exposure (Fig. 3A-D). In
agreement with earlier assessment of high inter-individual variation of
most of these parameters [28], values obtained per subject (controls
and patients) showed large differences. Markedly, however, only few
differences in these parameters were detected between the patientFig. 4. Flow-dependent adhesion of platelets with blood from patients and controls.Whole
through a collagen-coated PDMS chamber for 3.5 minutes at wall shear rate of 1600 s-1. Analyze
of DiOC6-labeled platelets (B). Patients using aspirin are represented by open squares. Bars indand control groups.With the patient blood samples, thrombi on collagen
were lower in morphological score, integrated feature size and
phosphatidylserine exposure (P≤ 0.02). None of the parameters differed
for thrombi formed on vWF/rhodocytin or vWF/fibrinogen.
Furthermore, real-time imaging of platelet adhesion to collagen
using DiOC6-labeled blood samples did not show differences between
the control group and patient group (Fig. 4A,B). Similarly, as reported
before [28], markers of thrombus formation – per surface and per pa-
tient/control sample – were correlated (data not shown). Together,
this indicated that for the patient group platelet adhesion, activation
and aggregation under flow was mostly unaltered compared to the
healthy, control group.
In vitro studies using blood samples from healthy controls were car-
ried out to specifically determine the effect of aspirin on the various
assay parameters. As indicated in Fig. 5, on collagen and to a lesser ex-
tent on vWF/rhodocytin (morphological score and phosphatidylserine
exposure), but not on vWF/fibrinogen, aspirin treatment reduced as-
pects of thrombus formation. Especially on collagen, thrombus parame-
ters were reduced by more than half.
Comparing the various parameters of collagen-dependent thrombus
formation per subject (patients and controls), gave high correlations
(P b 0.001, r2 =0.25-0.56, Spearman). This compares well with a previ-
ous systematic analysis of the thrombus-forming process with blood
fromhealthy subjects [28], and confirms that – in the absence of platelet
aberrations – the various platelet activation responses are highly linked.
Furthermore, compared per subject, markers of ADP- and collagen-
induced integrin activation (flow cytometry) strongly correlated with
parameters of collagen-dependent platelet aggregation under flow
(Table 2), pointing to a subject-dependent activation factor commonly
regulating both types of platelet responses.Discussion
A recentmeta-analysis of randomized trials indicates that in patients
with PAD, treatmentwith aspirin alone led to a statistically insignificant
decrease in cardiovascular events, but a significant reduction in non-
fatal stroke [40]. Several small-size studies have pointed to high activity
of platelets in PADpatients taking aspirin [20,21], which can be reversed
by the antiplatelet agent iloprost, a prostacyclin analogue [19]. Here, we
used high-throughput whole-blood assays, i.e. multi-agonist testing of
platelet activation by flow cytometry and multi-parameter testing of
thrombus formation onmicroarray spots, to determine the platelet acti-
vation tendency in 40 patients with PAD receiving aspirin compared to
healthy controls not on antiplateletmedication. This systematic analysis
points to a general high on-treatment function of the patient platelets in
thrombus formation, and thus supports the hypothesis that theblood pre-treatedwith DiOC6 from control subjects (c) and PAD patients (p) was perfused
d data per subject of brightfield images of platelet deposition (A) and integrative adhesion
icated mean and S.D. values (n = 40).
Fig. 5. Effect of aspirin onwhole-blood thrombus formation atmicrospot surfaces.Whole blood from control subjects was perfused over coatedmicrospots, as in Fig. 2. Blood samples
were incubatedwith vehicle or lysine acetylsalicylate (100 μM) for 10minutes at 37 °C prior to perfusion. Imageswere analyzed formorphological score, platelet deposition, staining for P-
selectin and phosphatidylserine (PS), as described for Fig. 3. Data are expressed as percentages relative to vehicle control. Means ± S.E.M. (n = 4), *P b 0.05.
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by an increased platelet activation profile after intake of aspirin.
In collagen-induced thrombus formation, platelet stimulation via
glycoprotein VI and ADP increases the affinity state of integrins α2β1
and αIIbβ3 [41,42], and leads to stable platelet adhesion and aggregateTable 2
Correlations of agonist-induced fibrinogen binding and P-selectin expressionwith param-
eters of thrombus formation on collagenmicrospots. Compared are analyses of platelet de-
position (brightfield % surface area coverage, SAC), aggregate size (integrated feature size,
IFS), and DiOC6 staining. Spearman correlation analysis of data from all subjects (n= 80);
given are two-sized P values per flow-cytometric data set. Colour scale from green to
white: low to high P values.formation [39]. Given that ADP is a primary agonist in establishing sta-
ble platelet-platelet interactions under flow [43], the similarity in
thrombus formation between the patient and control groups matches
the comparable ADP-induced integrin activation (fibrinogen binding)
in both groups determined by flow cytometry. This notion is confirmed
by the observation that markers of ADP- and collagen-receptor depen-
dent αIIbβ3 activation (flow cytometry) strongly correlated with
markers of the thrombus-forming process on collagen, which is indica-
tive of a common, subject-dependent regulation of both processes.
Although platelet activation and thrombus parameters in the patient
group were generally comparable with the control group, there were
some typical differences versus the healthy control group. The indica-
tion for increased platelet activity in PAD patients came from flow cyto-
metric analysis of platelet activation with low but not high CRP-xl
concentrations (stimulating glycoprotein VI). In contrast, decreased ac-
tivity in the PAD group was observed for TRAP-6-induced platelet acti-
vation (stimulating thrombin receptors), which is an aspirin-sensitive
response. Furthermore, we found moderate reductions in some (mor-
phological score, phosphatidylserine exposure), but not all (P-selectin
and platelet deposition) parameters of thrombus formation on collagen
in the patient group. Although these can be explained by the use of as-
pirin, the effect size appears to be smaller than observed by direct and
complete inhibition of control platelets with aspirin in vitro. In agree-
ment with the present results, others have also shown that aspirin
markedly affects thrombus formation on collagen under flow [44,45].
The seeming contrasting differences between increased stimulation
of patients' platelets with low doses of CPR-xl and reduced parameters
of collagen-dependent thrombus formation, can be explained by the
fact that, in thrombus formation under flow, not only glycoprotein VI,
but also other platelet receptors like integrin α2β1 and GPIb-V-IX are
determinative for this process [46]. This suggests a partly diminished
role of these other receptors in the patient group, concerning morpho-
logical score and phosphatidylserine exposure on collagen. The effect
on phosphatidylserine exposure yet is relevant, because this platelet re-
sponse is amajor trigger of coagulation factor binding and thrombin for-
mation on the platelet surface [47].
Strengths of this study are the relatively large size of the PAD pa-
tients (class IIa/IIb) and control groups; the use of well standardized
tests using whole blood samples with no platelet activation due to cen-
trifugation steps; and the ability to evaluate multiple platelet activation
processes and markers in the same tests. Given the overall consistency
of the various assay results, this study may help in improving the man-
agement and treatment of PAD, e.g. by considering more effective anti-
thrombotic pharmacoprotection.
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